Despite the risk of propofol infusion syndrome, a rare but often fatal complication of propofol infusion in ventilated children and possibly adults, propofol infusion remains in use in paediatric intensive care units (PICU). This questionnaire study surveys the current pattern of use of this sedative infusion in Australian and New Zealand PICUs. Thirty-three of the 45 paediatric intensive care physicians surveyed (73%), from 12 of the 13 intensive care units, returned completed questionnaires. The majority of practitioners (82%) use propofol infusion in children in PICU, the main indication being for short-term sedation in children requiring procedures. 39% of respondents consider propofol infusion useful in ventilated children requiring longer-term sedation. 67% of paediatric intensivists use maximum infusion doses that may be considered dangerously high (≥10 mg/kg/h). Nineteen per cent use propofol infusion for prolonged periods (>72 hours). A smaller proportion (15%) of respondents indicate that they may use both higher doses and prolonged periods of infusion, a practice likely to lead to a greater chance of serious adverse events. Knowledge of local protocols for the use of propofol infusion is associated with a significantly greater level of monitoring for possible adverse events. We suggest that national guidelines for the use of propofol infusion in children should be developed. These should include clear indications and contraindications to its use, a maximum dose rate and maximum period of infusion, with a ceiling placed on the cumulative dose given and clearly stated minimum monitoring requirements.
Propofol, a structurally unique sedative-hypnotic anaesthetic agent capable of depressing the central nervous system in a dose-dependent manner, is commonly used for sedation of intubated patients in adult intensive care practice [1] [2] [3] . Its use in this way for ventilated children however, remains controversial. The reported deaths of seven children who received propofol infusion in PICU in the early 1990s caused widespread concern 4-6 . The common clinical features in these cases were the development of lipaemia and metabolic acidosis in children (age range four weeks to nine years) with respiratory tract infections requiring mechanical ventilation. Soon after these reports in 1992, the Committee on Safety of Medicines (CSM) in the United Kingdom issued a serious adverse effect warning leading to the abandonment of propofol infusion as a sedative in most PICUs 7 . Subsequently, much has been published about the potential benefits and advantages of propofol over other sedation infusions 3, 8, 9 . Difficulties with dose titration, tachyphylaxis and physiological dependence for many of the drugs currently used for sedation in PICU, and the suggested benefits of propofol as an antioxidant with potential myocardial 10 and neuronal cell 11 protective effects, have led to a reexamination of propofol infusion in this setting. Our study aims to describe the current pattern of use of propofol infusion in Australian and New Zealand PICUs and to document the indications and contraindications to its use, the dose range and duration of infusion used and the level of monitoring of children on propofol infusion.
MATERIALS AND METHODS
A postal questionnaire (Appendix 1) was sent to all intensivists in Australia and New Zealand working in units solely or commonly caring for critically ill children. Respondents were asked to answer questions on their indications, contraindications, restrictions, dose-range and opinion regarding the usefulness of propofol infusion in PICU and to indicate whether their unit had a sedation protocol in place and whether this included propofol infusion. An initial questionnaire was piloted on four of the paediatric intensivists from the authors' PICU and changes were made to avoid ambiguity in questions included in the final study questionnaire.
All names and professional addresses were derived from a register of paediatric intensivists held by the Australian and New Zealand Intensive Care Society (ANZICS). The questionnaires were completed and returned between January and May 2001. No reminder letter or other communication was used. All questionnaires were made anonymous and remained confidential. Only respondents who indicated that they did use propofol infusion were included in the analysis of questions relating to indications, contraindications, monitoring, dosage and duration of infusion used and are referred to as positive respondents. All respondents, including those who did not use propofol infusion, were included in the analysis of the final question which asked the respondent to give an opinion of the usefulness of propofol infusion compared to other sedative infusions in PICU. Any respondents who did not indicate an opinion in this question were classified as "no opinion expressed".
The local research and ethics committee was informed of the details of this study prior to its commencement.
Data was analysed using Fischer's exact test and Jandel Sigmastat software. P values <0.05 were considered statistically significant.
RESULTS
Thirty-three (73%) of the 45 paediatric intensive care physicians surveyed from 12 of the 13 intensive care units in Australia and New Zealand returned completed questionnaires. Propofol infusion was used by at least one individual on each of the 12 units that responded. None of the respondents considered propofol to be a first-line sedative in ventilated children in PICU. Twenty-seven paediatric intensivists (82% of respondents) used propofol infusion in some children.
Thirty (91%) respondents were aware of a sedation protocol used in their PICU. In 10 of the 12 units that responded, at least one intensivist indicated that this protocol included propofol infusion. However, there was marked disagreement between physicians working in the same unit on this matter, with conflicting responses from physicians responding from the same PICU in 50% of cases. Seventeen (63%) of the 27 positive respondents indicated that a protocol for the use of propofol infusion existed in their PICU. Indications, restrictions and contraindications on the use of propofol infusion did not differ significantly between those positive respondents who indicated that their unit had a protocol in place for propofol infusion and those unaware of any such protocol ( Table 1) .
Indications given by positive respondents for propofol infusion in PICU are shown in Figure 1 . The most commonly stated indication for propofol infusion was to sedate children for invasive procedures (n=23 (85%)). A number of positive respondents indicated that they would use propofol infusion as a second, third or fourth line sedative infusion in ventilated children (n=13 (48%)), and for sedation in ventilated children with traumatic brain injury (n=11 (41%)).
Twenty placed at least one restriction on the use of propofol infusion. Twenty-two (82%) respondents stated a restriction on dose range, but the most common restriction reported was on duration of infusion (n=24 (89%)) ( Figure 2 ). Specifically, of the 27 positive respondents, 22 (81%) considered expected duration of infusion beyond 72 hours an absolute contraindication to its use ( Figure 3 ). Figure 4 shows the usual dose range used. Four (12%) positive respondents indicated that their usual propofol dose-range was 1 to 10 mg/kg/h. When asked to specify an upper dose limit, 18 (67%) posi-tive respondents indicated either no maximum dose limit (n=10), or a maximum dose limit greater than or equal to 10 mg/kg/hour (n=8) ( Table 1) . Four (22%) of this group of higher maximum dose users also did not consider an expected duration of propofol infusion greater than 72 hours to be an absolute contraindication. No significant difference in dose or duration of infusion was demonstrated between respondents indicating their PICU had a protocol for propofol infusion and those who did not ( propofol infusion in PICU indicated that they routinely monitored children on propofol infusion for cardiac arrhythmia. Twenty-two (81%) routinely monitored for metabolic acidosis and nine (33%) for the presence of lipaemia. Three (11%) individuals using propofol infusion in PICU did not routinely monitor children receiving this drug for any of the above. Awareness of the existence of a local protocol for propofol infusion in PICU was significantly related to greater monitoring of children for metabolic acidosis and cardiac arrhythmia ( Table 1 ). Thirty-one of the 33 respondents gave their opinion of propofol as a sedative infusion in PICU. The largest group (n=14 (42%)) considered propofol "as useful as other sedative infusions in PICU", with only 9% (n=3) of respondents stating propofol infusion has "no place in PICU" (Figure 5 ).
DISCUSSION
Our study reflects the views and practices of paediatric intensivists in Australia and New Zealand with regard to the use of propofol infusion in PICU. The high response rate (73% of paediatric intensivists returning completed questionnaires) makes this study broadly representative of the current opinion of those caring for critically ill children in Australia and New Zealand.
Most paediatric intensive care practitioners at the time of this survey do use propofol infusion in children in PICU, with the majority of respondents describing propofol infusion more useful or as useful as other sedative infusions in PICU.
The main indication reported for its use is for short-term sedation in children requiring procedures. In agreement with the use of propofol infusion in this way, a recent study found propofol to be effective and safe when administered as a continuous infusion after a loading bolus by intensivists in a properly monitored environment 12 . However, nearly half of those practitioners using propofol infusion in our study also consider propofol useful as a second, third or fourth line sedative infusion in ventilated children requiring longer-term sedation, a practice which has provoked much debate about its safety. A review of children with suspected propofol infusion toxicity ("propofol infusion syndrome") noted a common feature in these children was that they had usually received a high dose (>4 mg/kg/h) infusion for a prolonged period of time (>48 h). It was also noted, however that the child receiving the biggest dose showed no signs of propofol toxicity 14 . An evaluation of the pharmacokinetics and pharmacodynamics of short-term (4 to 13 hours) propofol infusion in 29 stable, mechanically ventilated children aged between birth and 18 years demonstrated great interpatient variation in blood propofol levels and pharmacokinetics 14 .
No relationship was observed between patient age and propofol pharmacokinetics and the reason for the variation described remains unclear. A threecompartment model characterized by a small central compartment into which the drug quickly distributes after intravenous infusion, and two much larger, more slowly equilibrating peripheral compartments, was found to best describe drug disposition. Propofol's pharmacodynamic effect is best reflected by the drug concentration in the central compartment, with the larger peripheral compartments probably acting as reservoirs for drug accumulation without contributing to its sedative effects. Despite the wide variation in propofol phamacokinetics between patients it was generally well tolerated, and based on their results, the authors recommended a dosing schedule (2.5 mg/kg loading dose followed by a descending dose infusion ranging from 7.6 to 4.3 mg/kg/h) for propofol as a sedative infusion in PICU 14 .
A few reports of propofol infusion syndrome have now also appeared in the adult literature 15, 16 . A retrospective cohort analysis of sedated, mechanically ventilated head-injured adult patients in a neurosurgical intensive care unit found evidence for the occurrence of propofol infusion syndrome, with an odds ratio for the occurrence of the syndrome of 1.93 for every mg/kg/h increase in propofol dose above 5 mg/kg/h 15 . The possible mechanisms of propofol toxicity remain unclear, but a relationship to the cumulative dose received may be inferred. Differences between children affected by propofol toxicity and those tolerating high doses have been postulated. These differences may relate to accumulation of a toxic metabolite affecting cellular metabolism in a number of organs 17 or to some other variation in drug pharmacokinetics 14 which becomes more apparent at high infusion rates. Wolf et al reported a child who developed the clinical features of propofol infusion syndrome and survived following treatment with haemofiltration, supporting the hypothesis that a water-soluble metabolite may be responsible for the toxic effects. This child showed biochemical abnormalities suggesting a specific abnormality of mitochondrial fatty acid oxidation, which returned to normal following recovery 18 .
A prospective study of nine children receiving propofol plus fentanyl infusions in PICU by Martin et al found no adverse clinical or biochemical derange-ments in children receiving 1 to 4 mg/kg/h for up to 48 hours 19 and advocated further large-scale studies to determine whether the warning against the use of propofol infusion in PICU was really justified. It is possible that combining propofol infusion with other drugs or infusions may have a propofol-sparing effect 20, 21 , so reducing the cumulative dose of propofol to which the child is exposed and decreasing the chance of serious adverse events. Our survey of current practice shows that the majority of paediatric intensivists are prepared to use maximum infusion doses that could be considered dangerously high (≥10 mg/kg/h) and a smaller number will use propofol infusion for prolonged periods (>72 hours). A proportion of respondents indicated that they would use both higher doses and prolonged periods of infusion, a practice likely to lead to an even greater chance of serious adverse events or death in some children.
Despite the potential advantages of propofol infusion over other sedative infusions used more commonly in PICU 10, 11, [21] [22] [23] , the most recent concern about the use of propofol in children under 16 years from the CSM 24 in the United Kingdom demands a complete reappraisal of the place of propofol in paediatric intensive care practice worldwide. A prospective clinical trial reviewed by the CSM randomized 327 children in PICU to receive propofol 2%, propofol 1% or other intravenous sedatives. It reported an increased mortality (11% vs 8% vs 4% respectively) and an increased incidence of adverse events in children receiving propofol infusion. This has led to the CSM recently advising U.K. practitioners that "propofol should be contraindicated in children of 16 years and younger". The study upon which the CSM has based its advice remains unpublished however, and therefore not subjected to the rigours of a wider, more generalized critique.
Most but not all intensivists using propofol infusion in our survey do monitor children closely for the development of serious adverse effects previously reported in association with propofol infusion. Significant differences in monitoring for serious adverse events, including cardiac arrhythmia and metabolic acidosis, were demonstrated between respondents aware and those unaware of the existence of a local protocol for the use of propofol infusion in their PICU. This is a somewhat unexpected finding given the usual minimum level of monitoring of any sedated child in PICU and may not accurately reflect actual practice. Nevertheless, a minority of children do appear to be inadequately monitored, given the unpredictability and idiosyncratic nature of the previously reported serious adverse events [4] [5] [6] .
In conclusion, the majority of paediatric intensivists surveyed in our study consider propofol to be a useful sedative infusion in PICU, predominantly for short, procedural sedation. However, our survey demonstrates a wide range in dosage, duration of use and levels of monitoring in children receiving propofol infusion in PICU. Whilst we accept a questionnaire survey of potential practice may not accurately reflect actual practice, the current pattern of use of propofol infusion documented in this survey may in some situations lead to children receiving high doses for prolonged periods. Such practice is associated with an increased chance of the development of serious adverse events or death. Despite the idiosyncratic nature of such events, knowledge of the common factors associated with many of the reported cases of fatal or near-fatal adverse events related to propofol infusion in PICU would suggest that the use of high dose or prolonged periods of infusion should be discouraged. We therefore suggest that national guidelines should be developed to guide the use of propofol infusion. These guidelines should include clear indications and contraindications to its use, a maximum dose rate and maximum period of infusion, possibly with a ceiling placed on the cumulative dose given, and minimum monitoring requirements expected in any child on propofol infusion.
